Skip to content

Effect of health management model based on intelligent medical treatment in elderly patients with nonalcoholic fatty liver disease

Effect of health management model based on intelligent medical treatment in elderly patients with nonalcoholic fatty liver disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037101
Enrollment
Unknown
Registered
2020-08-26
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease

Interventions

control group:Traditional model of medical and health management
experimental group:New health management model with the help of electronic information equipment and Internet technology

Sponsors

Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients older than 60 years old; 2. Patients with fatty liver confirmed by B-ultrasound; 3. Patients with certain language communication skills.

Exclusion criteria

Exclusion criteria: 1. Patients with drinking history or alcohol consumption more than 140g / week (female < 70g / week); 2. Patients with evidence of viral hepatitis, drug-induced liver disease, autoimmune liver disease, total parenteral nutrition, genetic diseases such as Wilson's disease, a - 1-antitrypsin deficiency and other diseases that may lead to hepatic steatosis; 3. Patients taking hypoglycemic, lipid-lowering, anti-inflammatory and weight-loss drugs, as well as any drugs known to affect liver function and coronary artery, kidney, lung and thyroid diseases; 4. Patients whose transaminase level is more than twice the upper limit of normal reference value; 5. Patients with serious heart, liver and kidney diseases; 6. Patients with mental or cognitive impairment; 7. Patients with dyskinesia.

Design outcomes

Primary

MeasureTime frame
FibroScan grading of fatty Liver ;Body weight, abdominal circumference, BMI;

Secondary

MeasureTime frame
Blood pressure, blood glucose, blood lipid and other metabolic indicators;IL-6, TNF - a and other inflammatory indexes;

Countries

China

Contacts

Public ContactHu Xiaona

Huadong Hospital

huxn06@163.com+86 13917654562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026